In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Marc Wortman

Advertisement
Set Alert for Articles By Marc Wortman

Latest From Marc Wortman

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Business Strategies Cancer

Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing

Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.

BioPharmaceutical Growth

Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane

The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.

Leadership Financing

F-Prime Plays The Long Game In Health Care Investing

With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.

BioPharmaceutical

Good Vs. Right Money: Choosing Optimal Financing Avenues For Biotech

Is all capital welcome? Investor attributes matter when raising capital and different attributes matter at different times in the life of a company, says a panel of investors and biotech leaders.

BioPharmaceutical Business Strategies

Here To Stay: Inception Sciences Shows Why Build-To-Buy Works

Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.

BioPharmaceutical Strategy
See All
Advertisement
UsernamePublicRestriction

Register